|
Age, years
|
55.9 ± 13.7
|
58.8 ± 14.0
|
56.9 ± 11.4
|
52.1 ± 15.1
|
0.124
|
|
Female, n (%)
|
46 (46)
|
16 (48.5)
|
14 (41.2)
|
16 (48.5)
|
0.785
|
|
Baseline Dialysis, n (%)
|
7 (7)
|
3 (9.1)
|
2 (5.9)
|
2 (6.1)
|
0.852
|
|
Baseline Serum Creatinine, mg/dL
|
1.23 ± 0.82
|
1.57 ± 1.09
|
0.88 ± 0.42
|
1.24 ± 0.66
|
0.002
|
|
Primary diagnosis of Oncology, n (%)
|
62 (62)
|
17 (51.5)
|
23 (67.6)
|
22 (66.7)
|
0.097
|
|
Hematologic Malignancy, n (%)
|
58 (93.6)
|
16 (94.1)
|
22 (95.6)
|
20 (90.9)
|
0.806
|
|
Primary diagnosis of Solid Organ Transplant, n (%)
|
26 (26)
|
14 (42.4)
|
5 (14.7)
|
7 (21.2)
|
0.097
|
|
Baseline AST, units/L
|
27.3 ± 36.0
|
22.0 ± 17.7
|
21.9 ± 15.5
|
36.4 ± 41.8
|
0.053
|
|
Baseline ALT, units/L
|
26.8 ± 28.2
|
22.2 ± 22.0
|
22.5 ± 22.1
|
37.1 ± 53.3
|
0.160
|
|
Baseline QTc, milliseconds
|
457 ± 40
|
478 ± 46
|
445 ± 29
|
450 ± 35
|
0.001
|
|
Concurrent echinocandin therapy, n (%)
|
23 (23)
|
8 (24.2)
|
5 (14.7)
|
10 (30.3)
|
0.298
|
|
Concurrent QTc prolonging medications, n (%)
|
83 (83)
|
24 (72.7)
|
28 (82.35)
|
31 (93.9)
|
0.057
|
|
Concurrent Immunosuppression, n (%)
|
52 (52)
|
20 (60.6)
|
17 (50.0)
|
15 (45.4)
|
0.447
|
|
Formal infectious disease team consultation, n (%)
|
71 (71)
|
28 (84.8)
|
20 (58.8)
|
23 (69.7)
|
0.055
|
|
Indication for use
|
|
Primary, n (%)
|
58 (58)
|
10 (30.3)
|
28 (82.4)
|
20 (60.6)
|
< 0.001
|
|
Refractory, n (%)
|
24 (24)
|
13 (39.4)
|
4 (11.8)
|
7 (21.2)
|
0.027
|
|
Intolerance, n (%)
|
16 (16)
|
9 (27.3)
|
1 (2.9)
|
6 (18.2)
|
0.011
|
|
Other, n (%)
|
2 (2)
|
1 (3.0)
|
1 (2.9)
|
0 (0)
|
0.444
|
|
Treatment diagnosis
|
|
Zygomycosis, n (%)
|
8 (8.33)
|
3 (9.1)
|
0 (0.0)
|
5 (15.2)
|
0.101
|
|
Aspergillosis, n (%)
|
30 (31.2)
|
12 (36.4)
|
10 (33.3)
|
8 (24.2)
|
|
Empiric treatment, n (%)
|
58 (60.4)
|
18 (54.6)
|
20 (66.7)
|
20 (60.6)
|
